A prospective trial of a personalized exercise program in patients with advanced prostate cancer
The Oncologist · 12.11.2026
DOI: 10.1093/oncolo/oyag452 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 12.11.2026. Verfasst von Benjamin L Maughan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Mays Cancer Center, UT Health San Antonio, San Antonio, TX. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The majority of patients with advanced prostate cancer (aPC) receiving androgen deprivation therapy (ADT) report fatigue as a major contributor to impaired quality of life (QOL). Herein, we evaluated the effect of a structured exercise program on fatigue in aPC.
Methods
Patients with aPC receiving ADT-based therapy were enrolled in a prospective clinical trial evaluating the impact of a 12-week, hospital-based, oncology-focused structured exercise program on fatigue. Eligibility criteria included receipt of hormone-therapy-based regimen for at least 4 weeks prior to enrollment, ≥4/10 tiredness in the prior week, sedentary lifestyle, no disease progression, and no chemotherapy within 3 months. Participants participated in weekly supervised 45-60-minute sessions either in person or via telemedicine and were encouraged to achieve ≥ 150 minutes of unsupervised moderate-intensity aerobic exercise per week, and to perform resistance exercises twice per week. Peak aerobic capacity, muscular strength/endurance, and symptom questionnaires were assessed at baseline and 12 weeks. The primary endpoint was change in PROMIS Fatigue 7a T-score; the key secondary endpoint was change in relative peak aerobic capacity.
Results
A total of 119 participants were enrolled. Of the 72 participants evaluable for the primary endpoint, there was a clinically significant 5.1-point reduction in fatigue (95% CI 3.6-6.7) by 12 weeks. Of the 76 participants who completed both aerobic fitness assessments, there was a 3.1 ml/kg/min (95% CI 2.1-4.0) clinically significant improvement in relative peak aerobic capacity by 12 weeks.
Conclusions
Completion of a 12-week exercise program led to clinically significant improvements in fatigue and exercise capacity in patients with aPC. These findings support routine recommendation of exercise for fatigue management in patients with aPC. (ClinicalTrials.gov identifier NCT03421782)
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology Oncology, Mays Cancer Center, UT Health San Antonio, San Antonio, TX.
- Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT.
- Department of Health and Kinesiology, University of Utah, Salt Lake City, UT.
- Cancer Control and Population Sciences Program, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Zitieren
APA
Maughan, B. L., Gebrael, G., Agarwal, N., Walker, D., Coletta, A. M., Nordblad, B., Swami, U., Gupta, S., Buys, S. S., Kohli, M., Hansen, P., Boucher, K., & Henry, N. L. (2026). A prospective trial of a personalized exercise program in patients with advanced prostate cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyag452
Vancouver
Maughan BL, Gebrael G, Agarwal N, Walker D, Coletta AM, Nordblad B, et al. A prospective trial of a personalized exercise program in patients with advanced prostate cancer. The Oncologist. 2026. doi:10.1093/oncolo/oyag452
BibTeX
@article{Maughan2026,
author = {Maughan, Benjamin L and Gebrael, Georges and Agarwal, Neeraj and Walker, Darren and Coletta, Adriana M and Nordblad, Blake and Swami, Umang and Gupta, Sumati and Buys, Saundra S and Kohli, Manish and Hansen, Pamela and Boucher, Ken and Henry, N Lynn},
title = {A prospective trial of a personalized exercise program in patients with advanced prostate cancer},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag452}
}
EUVIMED